“We have taken long strides over the past years…

We are very lucky to be living in an era in which cell and regenerative medicine is developing rapidly.”

— Dr. Xiang Hu

Research

Beike has been publishing groundbreaking research in the adult stem cell field for over 10 years utilizing umbilical cord blood and tissue as a source.

Beike’s Two Stem Cell Types

Beike provides and researches stem cells from two sources: umbilical cord blood and umbilical cord tissue. In some cases, the research protocols for some trials may include the use of more than one type of stem cells.

Umbilical Cord Blood-Derived Stem Cells (UCBSC)

For many ailments such as spinal muscular atrophy, ataxia, and optic nerve conditions, Beike Biotechnology has treatment using umbilical cord blood (UCB) stem cells. Our UCB stem cell injections consist of three subsets of stem cells: hematopoietic stem cells, endothelial progenitor cells, and mesenchymal stem cells. As has been shown in numerous studies, hematopoietic stem cells and endothelial progenitor stem cells are likely to form tissues in the body. Mesenchymal stem cells can assist in the growth of chondrocytes (a type of cell critical to tissue renewal, particularly cartilage), liver cells, kidney cells and neurons, and also conduct repairs in relation to vascular disorders within the brain, ocular areas, and throughout the body including the heart, kidney, and pancreas. At this stage of stem cell research, it is believed that the benefits patients report have come from the cell growth factors that are released by the stem cells after their administration.

Umbilical Cord-Derived Mesenchymal Stem Cells (UCMSC)

Based upon recent research publications and experience, Beike protocols utilize UCMSC stem cells for appropriate conditions. These injections contain a higher percentage of mesenchymal stem cells than the UCB stem cell injections and closely resemble the makeup of the injections cultured from patients’ own bone marrow. Currently, we recommend all multiple sclerosis (MS) and spinal cord injury (SCI) patients receive this type of stem cell injection as the cells not only produce important growth factors and differentiate into desired cell types but can also regulate the immune system, reducing inflammation, scarring, and cell apoptosis.

Below you can see Beike’s published research papers as well as clinical translation case studies for stem cell treatments of many different conditions. The papers are listed alphabetically.